Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

BMC Cancer

Case Report

Günther A. Rezniczek¹  Ziad Hilal¹  Clemens B. Tempfer¹  Franziska Hartmann² 

[1] Department of Obstetrics and Gynecology, Ruhr University Bochum, Bochum, Germany;Department of Pathology, Ruhr University Bochum, Bochum, Germany;

关键词: Ovarian cancer;    Intraperitoneal chemotherapy;    Maintenance;    Peritoneal carcinomatosis;    PIPAC;    Quality of life;    Antineoplastic agents;    Adverse effects;   

DOI  :  10.1186/s12885-016-3004-8

 received in 2016-09-30, accepted in 2016-12-15,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundPrimary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.Case presentationA 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy.ConclusionsRepeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.

【 授权许可】

CC BY   
© The Author(s). 2017